To investigate the clinical effect of hemodialysis combined with hemoperfusion combined with calcitriol on maintenance hemodialysis patients with secondary hyperparathyroidism.

Sixty patients with maintenance hemodialysis complicated with secondary hyperparathyroidism from January 2019 to June 2019 were enrolled, including 42 males and 18 females, aged 20-68 years, mean age(52±17.2)years. They were randomly divided into study group and control group, 30 cases in each group. The control group received routine hemodialysis 3 times a week, combined with calcitriol shock treatment; the study group received routine hemodialysis once a week, hemodiafiltration 1 time, blood dialysis filtration plus blood perfusion 1 time, combined with calcitriol shock treatment. The changes of serum calcium, blood phosphorus, blood parathyroid hormone and alkaline phosphatase (ALP) were observed in the two groups, and the clinical symptoms of the two groups were compared and analyzed.

The blood parathyroid hormone was decreased in both groups (P<0.05). The blood parathyroid hormone, serum phosphorus and alkaline phosphatase in the study group were significantly lower than that of the control group, the difference was statistically significant (P<0.05). The blood calcium level of the control group increased before and after treatment, and the difference was statistically significant. There was no significant difference in the serum calcium level between the study group and the control group (P>0.05).

Maintenance of hemodialysis patients with hyperparathyroidism by hemodiafiltration combined with blood perfusion and calcitriol shock treatment can not only effectively reduce blood parathyroid hormone, serum phosphorus and alkaline phosphatase levels, but also improve clinical symptoms and improve quality of life, not affecting the blood calcium levels of patients.